Jeff Warren - Vice President, Investor Relations
Omar Ishrak - Chairman and Chief Executive Officer
Gary Ellis - Chief Financial Officer
Mike Coyle - President, Cardiac and Vascular Group
Chris O’Connell - President, Restorative Therapies Group
Matthew Dodd - Citigroup
David Lewis - Morgan Stanley
Mike Weinstein – JPMorgan
Bob Hopkins - Bank of America
Kristen Stewart – Deutsche Bank
David Roman - Goldman Sachs
Larry Biegelsen - Wells Fargo
Matt Taylor - Barclays Capital
Medtronic, Inc. (MDT) F1Q 2014 Earnings Conference Call August 20, 2013 8:00 AM ET
Good morning. My name is Christie and I will be your conference operator. At this time I would like to welcome everyone to the Medtronic's first quarter earnings release conference call. (Operator Instructions) It is now my pleasure to hand the program over to Mr. Jeff Warren. Please go ahead.
Thank you, Christie. Good morning and welcome to Thank you, operator. Good morning and welcome to Medtronic’s first quarter conference call and webcast. During the next hour, Omar Ishrak, Medtronic’s Chairman and Chief Executive Officer; and Gary Ellis, Medtronic’s Chief Financial Officer, will provide comments on the results of our fiscal year 2014's first quarter which ended July 26, 2013. After our prepared remarks, we will be happy to take your questions.
First, a few logistical comments. Earlier this morning, we issued a press release containing our financial statements and revenue by business summary. You should also note that some of the statements made during this call maybe considered forward-looking statements and that actual results might differ materially from those projected in any forward-looking statement. Additional information concerning factors that could cause actual results to differ is contained in our periodic reports filed with the SEC. Therefore, we do not undertake to update any forward-looking statement.
In addition, the reconciliations of any non-GAAP financial measures are available on the Investors portion of our website at medtronic.com. Finally, unless we say otherwise, references to quarterly results, increasing or decreasing, are in comparison to the first quarter of fiscal year 2013 and all year-over-year revenue growth rates are given on a constant currency basis.
With that, I am now pleased to turn the call over to Medtronic's Chairman and Chief Executive Officer, Omar Ishrak.
Good morning and thank you, Jeff, and thank you to everyone joining us today. This morning we reported first quarter revenue of $4.1 billion, representing growth of 3% and non-GAAP diluted earnings per share of $0.88. While our results reflect that we are broadly outperforming the medtech sector, they were at the low end of our annual revenue outlook. However, we delivered on the bottom line, overcoming a number of challenges through strong operating discipline.
Looking ahead, our assumptions for the full fiscal year remained intact and we are confident in both our outlook for the remainder of the year and our long term competitive position in the changing healthcare environment. We continue strengthen and geographically diversify our business in order to deliver consistent and dependable growth. Overall, our Q1 results varied by business and geography with strong performances in some areas offset by challenges in other parts of our business. While our international operations performed well, growing 9%, our U.S. business declined 1%. This was driven by pressures in three distinct areas, CRDM implants, PAINSTIM and diabetes.
We expect full recovery in all three of these businesses within the fiscal year. So let me briefly walk you through the key dynamics. In CRDM we continue to grow our global implantable revenues meaningfully faster than the overall market. But our U.S implantable results were affected by lower levels of bulk sales because of the phase-in timing of our new high power products.
Gary will provide details later, but the net outcome was that the bulk sales were the lowest level in six years, affecting not only high power, but also our pacing business. At the same time, overall pricing dynamics improved and hospital inventory levels came down, which should improve our growth through the balance of the year. We fully expect to have our new technology on contract in our major accounts during Q2 at a price that reflects the proven clinical and economic benefits of our latest devices. This should result in a more typical level of bulk sales in the next quarter.
Turning to Europe, the business had a mixed quarter, with strong performances in DBS and gastro-uro, both posting at or near double digit growth, offset by declines in U.S PAINSTIM. We received FDA approval for our game-changing MRI system much earlier than expected and made the decision to transition manufacturing in Q1 and observed supply constraints in both previous and new products. This family of products is now launching in the U.S., and while it is still early in the quarter, they’re being well received by our customers, and the PAINSTIM business has resumed its growth.
In U.S Diabetes, we had another challenging quarter declining 3%, but this was by no means unexpected. As we mentioned last quarter, the business will remain under pressure until we receive approval of the MiniMed 530G system. We continue to work diligently with the FDA so that we can make this important technology available this fiscal year. Upon launch, we expect our U.S Diabetes business to return to solid growth on the strength of our new products and our ability to recognize revenue we have deferred over the past few quarters.
Now, let me discuss the rest of our business with a number of positive highlights. In our spine business, core spine outperformed a relatively stable market as our new products in enabling technologies continued to make a difference. Our U.S. core spine business, excluding balloon kyphoplasty grew 1% this quarter. In BMP, the declines appear to be tapering, and we saw relative sequential stability again this quarter. The independent reviews of Infuse commissioned by Yale University were completed in Q1, providing further evidence that for approved indications, Infuse is a safe and effective treatment option.
Later this fall, we are expecting final publication of our retrospective analysis of a large, national payer database investigating the cancer incidents in the real world usage of Infuse. The manuscript of that study was recently published online, ahead of print by the Journal Spine. The authors found no evidence that administration of BMP at the time of lumbar fusion surgery was associated with cancer risk. Looking ahead, if current trends continue, we expect our global FY 2014 BMP revenue to be down in the mid-single digits which would be a significant improvement from the 15% decline last fiscal year and would represent a 40 to 50 basis point improvement to our overall company growth.
In U.S coronary, drug-eluting stent sales exceeded our expectations, solidly outperforming the market with 4% growth, despite having annualized the launch of Resolute Integrity. Our international regions continued to deliver solid results. As I mentioned earlier, revenue was up 9%, driven principally by Japan and emerging markets. Our international regions have now grown in the upper single digits for 12 consecutive quarters, which is the type of consistent and balanced performance that we’re looking for. Japan had another outstanding quarter, up 29%, driven by the continued success of our new products, including the Advisa MRI pacemaker, Resolute Integrity DES, and Endurant II AAA Stent Graft.
In Western Europe, while our growth was aided by advanced purchases of CoreValve in Germany, we did see another quarter of relative stabilization across the region. Our European team is navigating through the various market dynamics to unlock potential growth opportunities using innovation as well as our breadth and scale to partner with different stakeholders.
Emerging markets grew 15%, with strong performances from Middle East and Africa and Central and Eastern Europe regions, partially offset by pressure in Latin America and India. Latin America was softer than expected this quarter as we transitioned from some of our dealers to direct sales. Our India region declined as we faced challenges from government imposed pricing reductions for stents as well as temporary disruption from the termination of a coronary distributor. Looking ahead, we remain focused on high-teens growth in emerging markets in the near term while striving for 20% or better over the long term. We believe these markets will continue to provide an independent growth vector for us, becoming an increasingly significant source of consistent and reliable revenue over time.
Let's now turn back to the U.S. region. As I discussed previously, we expect to fully recover from the specific challenges we faced this quarter, but we also have an additional number of exciting growth drivers which should significantly improve our performance in the U.S. over the next seven quarters. And it's worth spending a few moments to briefly highlight them. First, in addition to the recently launched Viva CRT-D, Evera ICD, and Advisa MRI pacemaker products, the CRDM business plans to launch the Reveal LINQ late this fiscal year. This is our next generation implantable loop recorder which would expand our offerings across the patient continuum of care.
In endovascular, we are expecting approval of a dissection indication for the Valiant Captivia Thoracic platform along with obtaining an SFA indication for the complete SE Vascular Stent in peripheral. In spine, similar to our SOLERA platform in thoracolumbar, we are planning a complete refresh of our anterior cervical plate family of products. Starting with expected approval of our PRESTIGE LP Cervical Disc, we will launch a series of additional new products over the coming quarters. Cervical makes up nearly a quarter of our U.S. core spine business and these launches should enhance our competitive position.
In surgical technologies, we are developing the next iteration of our highly successful O-arm Imaging System which will expand a number of supported clinical applications and therefore increase further its economic value proposition for hospitals. I would also like to note that Cardiocom, the new service and solution acquisition that we announced last week will also immediately start contributing to our growth. I will discuss Cardiocom in more detail in a moment.
And finally, we are making excellent progress on three fundamental new therapy areas that meaningfully impact our outlook for FY 2015 and beyond, our CoreValve transcatheter aortic valve, our renal denervation system for treatment resistant hypertension, and our Admiral drug-eluting balloon. These products are market leaders in Europe and we are planning to launch all three of them in the U.S. with CoreValve and Symplicity in FY '15, and Admiral in FY '16. Regarding CoreValve, we have filed with the FDA, all the extreme risk modules for our U.S. pivotal trial, and are preparing for launch in the first half of FY 2015.
Extreme risk data will be included in late breaking clinical trials at TCT later this fall, and the high risk data is expected to be presented at the ACC next spring. With respect to Symplicity, we have completed patient randomization in our U.S. HTN-3 pivotal trial, and we expect the results to be presented sometime in the first half of calendar year 2014, while targeting U.S. approval in FY '15. In addition, we expect the FDA and CMS parallel review program to reduce the time between FDA approval and full reimbursement. For the Admiral DEB program, we completed enrollment in our initial SFA pivotal trial and have submitted our first PMA module.
Turning now to the rest of the P&L. Our organization delivered at the bottom line despite multiple pressures. Revenue came in a little lighter than expected. We had a higher than expected share count. There were significant FX headwinds, and our gross margins were negatively impacted by specific quality issues. Gary will cover all of these items in more detail later, but on the final point I want to emphasize that while diverting resources to enhance our quality systems can be costly, ensuring the highest level of quality and regulatory compliance has and always will be a personal priority for me and a central focus of everything that we do at Medtronic.
At the same time, we continue to make progress in a number of key operating initiatives, including product cost reduction and working capital improvements. We are in the middle of $1.2 billion product cost reduction initiative, which helps us successfully offset pricing pressure and stabilize gross margins. In our working capital improvement program, we have set a goal of increasing our inventory turns by 50% in FY’17. Not only does this instill good fiscal discipline, but it strengthens our already robust levels of free cash flow generation.
Over the next five years, we expect to generate over $25 billion of free cash flow. We remain committed to returning 50% of this to our shareholders through dividends and share repurchases, a commitment level we believe is appropriate given our current mix of U.S. and international free cash flow. We are constrained by U.S tax policy which creates a negative incentive for us to repatriate cash to the U.S. The remaining 50% gives us the flexibility to make the necessary investments for sustainable growth. We continue to be very disciplined in how we deploy our capital with a strong focus on returns. As we have said in the past, we expect any M&A transaction to surpass our mid-teens risk-adjusted hurdle rate, and we do not expect these investments to be dilutive to shareholder EPS growth expectations.
We have spoken in some detail regarding our ongoing strategic commitment to new therapies. But I want to conclude by noting that we continue to take meaningful actions to realize our transformational opportunities of globalization and economic value. We believe successful execution of both of these areas will position us to win in the changing healthcare marketplace and will be instrumental in establishing durability in our long term performance while creating potential upside to our baseline expectations.
Consistent with our focused strategy to generate economic value from multiple stakeholders, we are specifically exploring two areas where we can offer important solutions for healthcare systems around the world; disease management and hospital efficiency. First, in disease management, we announced the acquisition of Cardiocom, a leading developer and provider of integrated solutions for chronic disease management. Cardiocom is an example of how we can pair our existing market-leading therapies with a set of complementary services and technology solutions that treat broader patient populations across the care continuum.
Our combined offerings have the potential to concurrently improve outcomes and lower costs by reducing hospitalizations, improving remote clinical management and increasing patient engagement. These benefits are particularly compelling to a wide set of stakeholders, including governments, payers and hospital systems because they provide enhanced clinical and economic value over the long term. Our initial focus with Cardiocom will be heart failure and hypertension, versus building long term plans to offer complete solutions in our key chronic disease verticals of cardiovascular and Diabetes, striving to not only improve individual patient lives, but also ensuring that the overall healthcare ecosystem remains viable.
The second area where we expect to generate significant economic value for our customers is hospital efficiencies. As we continue to work closely with hospital administrators around the world, we understand that they are deeply concerned with driving efficiency and optimizing the overall cost of operations. We’re working together to develop innovative solutions for these problems, including implementing process improvements, adopting new financing models, deploying new purchasing and venture management strategies, and outsourcing certain functions. In the coming weeks, you will hear more about our hospital efficiency efforts and I look forward to discussing them in more detail as they’re announced.
In closing, I would like to add that the challenges facing healthcare are not easily solved. But we believe we’re uniquely positioned to increase our competitive advantage in the changing healthcare landscape by offering solutions that improve the financial viability of global healthcare systems. Our market leading products, in-hospital systems, healthcare economic expertise, leading (inaudible) resources, and our strong financial position give us unprecedented breadth, global reach and scale, and allow us to offer broad, valuable solutions. We are determined to transform Medtronic from being a primarily device provider today into the premier global medical technology solutions partner of tomorrow.
Let me now ask Gary to take you through a more detailed look at our results before we take any questions.
Thanks Omar. First quarter revenue of $4.083 billion increased 2% as reported and 3% on a constant currency basis after adjusting for our $55 million unfavorable impact of foreign currency.
Q4 revenue results by region were as follows. Growth in Middle East and Africa was 24%. Central and Eastern Europe grew 21%. Growth in Asia Pacific was 20% driven by 29% growth in Japan. Growth in greater China was 15%. Latin America grew 12% and western Europe and Canada grew 2%. While the U.S. declined 1% and India declined 7%. The emerging markets grew a combined 15% in Q1 and represented 12% of our total sales mix.
Q1 delivered earnings per share on a non-GAAP basis were $0.88, an increase of 4%. Q1 GAAP diluted earnings per share were $0.93, an increase of 12%. This quarter's non-GAAP pretax adjustments included an $18 million restructuring charge, the final charge related to the initiative we announced last quarter. A $40 million cash charitable donation to the Medtronic Foundation, and a $96 million gain primarily related to the change in fair value of our RDN contingent consideration payments, which are based on annual revenue growth through FY '15.
Given the current slower commercial ramp in Europe and the extended U.S. regulatory process, we now expect our contingent consideration payments to be reduced as addition of the RDN business has now shifted beyond the final revenue milestone date. In our cardiac and vascular group, revenue of $2.160 billion grew 4%. The results were driven by solid growth in Structural Heart, Pacing, Endovascular, AF Solutions and Coronary, partially offset by a modest decline in U.S. ICDs.
CRDM revenue of $1.193 billion grew 2%. Worldwide ICD revenue of $655 million declined 2%, roughly in line with the market. In the U.S., our ICD revenue declined 4% below the market which we estimate declined 2%. As Omar mentioned, due to the phase and timing of our new products, there were many instances where we were not able to get our new products and their associated pricing premiums on new hospital contracts before the end of the quarter. And we were generally unwilling to offer bulk discounts for our latest technology off the previously contracted price.
Concurrently, some hospitals chose to make stocking purchases ahead of our new products being available on their new contract which lead to meaningfully lower levels of bulk sales in the quarter. At the same time, our U.S. ICD implant dynamics changed markedly during the quarter following the mid-quarter release of Viva and Evera with the daily implant growth rate shifting from negative to positive in the back half of the quarter. Our lead differentials remain at elevated levels and our U.S. ICD pricing continues to show signs of relative stability, declining 2% year-over-year as both our Viva CRT-Ds and Evera ICDs received price uplifts in the market.
As Omar mentioned, bulk sales were significantly lower in Q1 and were responsible for our entire revenue decline as daily implant revenue actually grew 1%. We believe our top technology tiers and high power are now significantly differentiated in the market place, which allows to minimize pricing pressure and stay very disciplined on new product pricing. We are seeing good market adoption of Viva and Evera. Viva has our proprietary adaptive CRT algorithm which significantly reduced RV pacing and has been clinically proven to improve response rates of CRT therapy, resulting in improved device longevity and a reduction in the heart failure hospitalizations.
In addition, our Attain Performa quadripolar lead along with our VectorExpress implant optimization algorithm, is driving differentiated CRT-D market share capture in Europe, and will be available in all major markets outside of the U.S. by the end of the fiscal year. Finally, both the Viva CRT-D and Evera ICD contain enhanced shock reduction algorithm, battery and circuit design improvements to extend device longevity, and the unique PhysioCurve design, which meaningfully reduces device size and enhances patient comfort. Pacing revenue of $474 million grew 6%, outperforming the global market by 450 basis points. Our international pacing business grew 14%, driven by the strong customer demand for our Advisa MRI pacemaker in Japan.
AF grew in the mid-teens, driven by over 20% growth of our Arctic Front Advance cryoballoon system as customers continue to adopt this second generation system due to its more efficient, safe and effective treatment for paroxysmal AF.
Coronary revenue of $435 million grew 3%. Worldwide, DES revenue in the quarter was $273 million, including $105 million in the U.S and $25 million in Japan. Resolute integrity’s deliverability, positive data regarding early dual antiplatelet therapy interruption, unique FDA labeling for Diabetes, and long term clinical performance is receiving strong customer acceptance globally, despite competitive product launches of next generation products. Resolute integrity is also the one product line that is featured in virtually every one of the CVG multi-line product contracts we execute.
In renal denervation, while Q1 revenue continued to be modest, we are investing in developing referral networks, reimbursement, technology development and clinical and economic evidence to further strengthen our leadership position for this large, long term opportunity in hypertension. We are now anticipating CE mark for our next-generation Symplicity Spiral multi-electrode catheter before the end of the fiscal year.
On the clinical front, we received IDE approval from the FDA earlier this month for Symplicity HTN-4, which is focused on expanding the indication to include uncontrolled hypertension patients with systolic pressure between 140 mm and 160 mm of mercury.
In structural heart, revenue of $313 million increased 13%, driven by strong growth in our transcatheter valves transacts, including a meaningful acceleration of advanced customer purchases of CoreValve in Germany. Excluding the meaningful acceleration of advanced customer purchases of CoreValve in Germany, excluding this impact, we estimate the international transcatheter valve market grew in the upper single digits. In Germany, the Spenser patent injunction ruling has been a significant disappointment to customers who are concerned about having access to our market leading transfemoral technology, and the increased difficulty they will experience in accessing our unique valve size, catheter size and indications for use options. We respectfully disagreed with and have appealed the court’s decision. We ultimately believe that the Spenser patent should be found to be invalid. And we, along with many others, are challenging the validity of the European Patent Office.
In Q1 we became the first company with CE Mark approval for valve and valve procedures using CoreValve and CoreValve Evolut. We also continued the launch of our Engager valve in Europe, our entry into the transapical segment, which represents approximately 20% of the European TAVI market. In addition, the first implant of Engager direct aortic occurred in July and we expect CE Mark approval for this product in FY15.
In endovascular, revenue of $219 million grew 7%, with solid growth in both our aortic and peripheral businesses. In aortic, strong growth continued in Japan with the launch of our Endurant II AAA Stent Graft system. Our thoracic products grew over 20% on the strength of the Valiant Captivia in the U.S. and international markets.
In peripheral, our market leading drug-eluting balloon posted strong double-digit growth.
Now turning to our Restorative therapies group. Revenue of $1.554 billion grew 3%. Results were driven by growth in surgical technologies, neuromodulation, and Core Spine, partially offset by declines in BMC. It is worth noting that starting this quarter, Diabetes will be reported as a separate group and is no longer part of the Restorative Therapies Group. Spine revenue of $765 million declined 1%.
Core spine revenue of $641 million grew 1%. Excluding BKP, our core spine business grew 3% globally and 1% in the U.S, outperforming the market. The U.S. core spine market continues to show signs of stability, with a low single digit price mix decline and flat procedure volumes. Our new procedures and technologies, including our Solera posterior fixation system, Bryan Artificial Cervical Disk, Premium DBMs and AMT interbody devices are driving growth in our core spine business.
We are also differentiating our spine business from the competition through enabling technologies that we leverage from our surgical technologies business, including O-arm imaging, StealthStation navigation and POWEREASE power surgical instruments. Hospitals are investing in our capital equipment for spine surgery as they seek clear value from improved surgical precision and more efficient procedures. We are still early in realizing this large differentiated opportunity in spine which is resulting in increased revenue and share for our spinal implants as well as solid growth of our capital equipment in our surgical technologies business. Our Kanghui orthopedics business in China continues to perform well with its revenue growing in excess of 20% and offsetting the lost revenue from our former Weigao joint venture.
Turning to surgical technologies. Revenue of $361 million grew 13% with double-digit growth in all three businesses, ENT, neurosurgery, and advanced energy. The strong performance in ENT is attributable to solid growth in image guided surgery and monitoring, as well as the successful launches of TriVantage EMG Tube and the Indigo high-speed Otologic drill. Neurosurgery, which grew 12%, was driven by capital upgrades of the StealthStation S7 surgical navigation system. Advanced energy had another outstanding quarter as it strategies to focus on its four core markets of orthopedics, spine, breast and CRDM replacements resulted in growth of over 20%.
Turning to neuromodulation. Revenue of $428 million increased 3% on solid global growth in DBS and gastro uro. DBS delivered another strong quarter driven by double-digit new implant growth in the U.S. In addition, data from our EARLYSTIM trials which was published earlier this year in the New England Journal of Medicine, is generating significant interest in international market. In gastro euro, we had strong mid-teens growth of InterStim therapy in Western Europe. In PAINSTIM, results came in below our expectations this quarter as customers awaited the launch of the RestoreSensor SureScan MRI spinal cord stimulation system in the U.S. This product launched earlier this month and we expect this innovative technology to drive growth and share gains in the coming quarter.
Now turning to our diabetes group. Revenue of $369 million grew 1% and international markets growth was 8% as we continue to see strong adoption of the Veo pump with low-glucose suspend and Enlite CGM sensor. In the U.S. revenue declined 3% as customers continued to anticipate FDA approval of the MiniMed 530G, the U.S. version of this pump and sensor. We have now deferred $33 million of revenue including $11 million in Q1, as some customers plan to upgrade to the new technology when it's available. We have diverted significant people and resources to do everything possible to address the FDA's quality system findings quickly and effectively. This diversion is negatively affecting the timing of our upcoming product launches and we now expect our next generation pump platform, the MiniMed 640G, to launch in international markets in the second half of this fiscal year.
Turning to the rest of the income statement. The Q1 gross margin was 75%. After adjusting for a 30 basis point negative impact from foreign exchange, the Q1 gross margin on a non-GAAP operational basis was 75.3%. It is also worth noting that the gross margin includes significant spending related to resources diverted to address quality issues in neuromodulation and diabetes, which negatively affected the gross margin by 40 basis points. Looking ahead, we would expect the gross margin for fiscal year 2014 to be in the range of 75% to 75.5% on an operational basis.
Third quarter R&D spending of $316 million was 8.8% of revenue. We continue to invest in new technologies and evidence creation to drive future growth. We would expect R&D expense in fiscal year 2014 to be around 9% due to the tradeoffs we are making go partially offset the device tax, as well as shifting R&D resources to resolve pending quality issues, which gets recognized in cost of goods sold. First quarter SG&A expenditures of $1.416 billion represented 34.7% of sales. After adjusting for the 20 basis point negative impact from foreign exchange, Q1 SG&A was 34.5%.
We continue to focus on several initiatives to leverage our expenses. In FY '14 we would expect to drive 30 to 50 basis points of improvement, which would result in SG&A in the range of 33.8% to 34% on an operational basis. And it is worth mentioning that we typically see most of our leverage in the fourth quarter. Amortization spend for the quarter was $86 million. For FY '14, we would expect amortization expense to be approximately $85 million to $90 million per quarter. Net other expense for the quarter was $44 million. Net gains from our hedging program were $18 million. As you know, we hedge the majority of our operating results in developed market currencies to reduce volatility in our earnings from foreign exchange. However, recent movements in unhedged currency exposures is creating increased headwind for the remainder of the fiscal year.
Based on the current exchange rates, we expect FY14 net other expense to be in the range of $100 million to $220 million, which includes an expected $120 million impact from the U.S. Medical Device tax. For Q2 FY14, we expect net other expense to be in the range of $45 million to $55 million, based on current exchange rates.
Net interest expense for the quarter was $40 million. At the end of Q1, we had approximately $11.3 billion in cash and cash investments, and $11.2 billion in debt. Based on current rates, we would expect FY14 net interest expense to be in the range of $150 million to $160 million.
In Q1, we generated $891 million in free cash flow. As Omar emphasized, we are committed to returning 50% of our free cash flow to shareholders. In Q1, we paid over $280 million in dividends and in June, our board approved an 8% increase in our quarterly dividend which puts our payout ratio at approximately 30% and is the 36th consecutive year we have increased the dividend. We also repurchased over $1.3 billion of our common stock. As of the end of Q1, we had remaining authorization to repurchase approximately 81 million shares. First quarter average shares outstanding on a diluted basis were 1.021 billion shares.
Our fully diluted share count is higher than expected, primarily due to the recent movements in Medtronic’s share price. Consequently, we have seen an increase in stock options being exercised which has resulted in more shares being issued. However, it’s important to note that the cash we receive from these stock option redemptions which was $560 million in Q1, was used to repurchase shares in the open market to offset some of the dilutive impact. These share repurchases are incremental to our commitment to return 50% of our free cash flow to our shareholders.
Let’s now turn to our tax rate. Our effective tax rate in the first quarter was 17.3%. Excluding the impact of unusual items, our non-GAAP nominal tax rate in the first quarter was 19.5%. Included in our tax rate for the quarter is $3 million net benefit associated with the finalization of certain tax returns and changes to uncertain tax position reserves for the quarter. For fiscal year 2014, we continue to expect a non-GAAP nominal tax rate in the range of 19% to 20%.
Let me conclude by providing our fiscal year 2014 revenue outlook and earnings per share guidance. Based on the stabilization trends in our businesses, as well as our first quarter performance, we continue to believe that full year constant currency revenue growth of 3% to 4% remains reasonable for fiscal year 2014. While we cannot predict the impact of currency movement, to give you a sense of the FX impact, if exchange rates were to remain similar to yesterday for the reminder of the fiscal year, then our FY14 revenue would be negatively affected by approximately $190 million to $230 million, including a negative $40 million to $60 million impact in Q2.
Turning to guidance on the bottom line, we continue to expect FY14 non-GAAP diluted earnings per share in the range of $3.80 to 3.85, which implies annual earnings per share growth of 6% to 8% on an operational basis after adjusting for certain tax benefits that we received in FY13 as well as the headwinds from the medical device tax and incremental interest expense in FY14. It is also worth noting that while we do not providing quarterly guidance, when looking at the quarterly earnings per share consensus and the continued uncertainty on the timing of Diabetes MiniMed 530G approval as well as the FX headwinds, we would not be surprised to see some models shift 2 to 3 pennies from Q2 to Q4. As in the past, my comments on guidance do not include any unusual charges or gains that might occur during the fiscal year.
I will now turn it back over to Omar, who will conclude our prepared remarks. Omar?
Thanks, Gary. Before opening the lines for Q&A, let me briefly conclude by reiterating that in the end, Q1 was a solid quarter, despite a number of challenges. While 3% topline growth is consistent with the outlook we provided at the beginning of the year, it was softer than we expected and fell just below our mid-single digit baseline goals. However, I also want to emphasize that our team executed well to deliver on the bottom line. And looking ahead, we remain confident in our outlook for the remainder of the year.
We continue to focus on strengthening and geographically diversifying our business so that we can deliver consistent and dependable growth. Although there will always be pressures in the dynamic environment, we intend to execute in areas that we can control. Including growing our markets and building our business so that it is resilient enough to offset the variables that are beyond our control. And overtime, we are striving to reliably deliver on our baseline expectation which are, consistent mid-single digit revenue growth, consistent EPS growth, 200 to 400 basis points faster than revenue and returning 50% of our pretax growth to shareholders.
At the same time, we are positioning Medtronic to play a leading role in global healthcare by executing in our transformational opportunities of new therapy development, economic value and globalization. We believe that crisp execution on both our baseline and long-term growth strategy, combined with strong and disciplined capital allocation, will enable us to create long-term dependable value in healthcare.
With that, we would now like to open the phone lines for Q&A. In addition to Gary, I have asked Mike Coyle, President of our Cardiac and Vascular Group, and Chris O’Connell, President of our Restorative Therapies Group, to join us again for the Q&A session. We’re rarely able to get to everyone’s questions, so we respectfully request that you limit yourself to only one question and if necessary, one follow up, so that we can get to as many people as possible. If you have additional questions, please contact our investor relations team after the call.
Operator, first question please.
Our first question comes from the line of Matthew Dodd with Citigroup.
Matthew Dodd - Citigroup
I wanted to focus first on pricing. Omar and Gary, you both highlighted CRM sounded a little better in the U.S., down 2%. Can you comment on what pacing was in the U.S., maybe what stents were, and then broadly, how Europe is behaving? I am trying to see if some other comments from your competitors about pricing looking a little better, if you agree with that view broadly.
I will let Gary address this.
Yeah, Matt, overall as you indicated, we saw a little bit of a -- obviously in ICDs, we saw tempering of the kind of decline, down a couple of percent. Pacing was also kind of down at low single-digits and so we saw good improvement there. Stents, I think it has been, it varies kind of around (inaudible) -- they have been probably closer more in the high-single digits as far as some of the declines there depending on what geography you are in. So if we continue to see pricing declines on the drug-eluting stent side that are pretty consistent with what we have seen over the last several quarters. But clearly with the new product launches we had both in pacing and on the high power, we are seeing a little bit of tempering on the pricing pressure.
Matthew Dodd - Citigroup
And then just one quick ICD question. When you look at the bulking, Q4 didn’t factor into Q1, is the comments from call, you got a hit in Q1 but you expect to improve in Q2 or do you think Q4, there was some additional bulking on that quarter that impacted Q1?
I think largely you are correct. I think it was mostly Q1 isolated the Q1 itself and the dynamics are between Q1 and Q2 as opposed to Q4.
Yeah, Matt, as we look through, we clearly saw a dip at the end of the quarter. We know inventory levels dropped based on what we saw as far as implant usage and everything else. And so, we don’t believe that there was a big impact from Q4. Obviously, our Q4 was a very strong quarter as you all know, but that -- we don’t think that that had an impact on the quarter. We do believe, we know as we indicated in the comments, that a lot of these new products were not on contract yet, and we weren’t willing to put discounts on the previously contracted pricing. And so as a result of that, we just didn’t see the level of bulk purchases during the quarter that we would normally see. And we know inventory levels are down as a result of that, so that bodes well for the future. We think it bodes well not only for pricing but obviously also we would expect the bulk purchases to come back to more normal levels as we go through the rest of the year.
Your next question comes from the line of David Lewis with Morgan Stanley.
David Lewis - Morgan Stanley
Maybe just two quick questions. Gary, just in terms of the German injunction impact for CoreValve, it looked to us like about a $25 million impact. Can you kind of give us a sense of what the impact was in your mind in the quarter and how do we think about that number heading into next quarter? Should we assume a significant drop off or still inventory levels are maintaining a relatively high? And then I have a quick follow-up.
Well, again, I will try to -- we don’t know obviously, David, exactly how much benefit we received in the quarter from the advance purchases. We know that customers were buying in advance of the anticipated injunction. And so, as a result of that, that clearly had a benefit in the quarter. We know that our results were higher than what was going on in the market during that period of time. The numbers are anywhere from (inaudible) is a little high, but overall we’re probably somewhere in that ballpark. The reality is we did have extra revenue during the quarter. As we go into Q2 and Q3 it will obviously depend on as the (inaudible) even in the quarter, we continue to be selling until the injunction is in effect and we’ll continue. So, there will be some impact obviously in the quarter. Whenever the injunction – when that occurs, if that occurs, then obviously it will have an impact going forward and it will be spread out over that period of time until that exit that – we get that resolved. But at this point in time, obviously it was an advantage in Q1 we’re aware of. So, inventory levels obviously are higher on that product currently. Inventory levels on CRDM obviously are lower in the U.S., but clearly on CoreValve they are higher as physicians bought in anticipation of a potential injunction.
David Lewis - Morgan Stanley
And then maybe, Omar, just more of a strategic question. All throughout the quarter we heard the Chinese government taking greater action to look at price scrutiny in obviously the domestic market. Most of that was directed at pharmaceutical providers, but there has been some around medical device manufacturers. Historically when we've seen this action by the government we have seen an impact on growth rates in China for drugs specifically, but also somewhat for devices. Any sense of what impact some of the government's actions are having on your business or is there any concern that you would see an impact on your business later on in the year? Thank you.
Look, we’re watching China closely for obvious reasons. Now, the first thing that I’d like to say is that in no way does any of this activity shake our belief that it is a market we’ve got to win and we’ve got to be committed to, and we’ve got to understand locally how it operates. Now, you’re right that the Chinese government is looking at pricing very carefully and probably as they should. But in our view, most of that is directed around go-to-market models using distributors, which we are looking at very carefully. It’s a market where we eventually have to have more direct presence with the customers themselves. Now, the way we have traditionally gone to market, we use distributors for a variety of reasons, a lot of those extremely necessary.
And so we don’t want to make any dramatic changes, but we are, as we’re doing in almost every other country in the world, examining our distribution models very carefully. That’s the action that we’re taking, and at the same time we’re working very closely with the government to help put in the investment, so that healthcare in China can be dramatically improved. So again we’re watching the situation closely, particularly on the distribution channels, but we don’t expect at this stage any dramatic moves anytime soon. And again, as I said, we’re just watching it.
Your next question comes from Mike Weinstein with JPMorgan.
Mike Weinstein – JPMorgan
First question is just a follow-up on the CoreValve discussion. When do you expect there to be a validity decision in Europe that would impact Germany?
Mike, do you want to take that?
Our expectation is next spring, we would have a decision in that hearing.
Mike Weinstein – JPMorgan
Okay. Omar, on our call in June you talked a fair amount about building a comprehensive presence across all of the different platforms at Medtronic; Cardiovascular, Restorative, and Diabetes. Can you maybe just spend a few minutes talking about that and how in particular in Diabetes and Restorative that you think about how you want that business to look over the next let's say three to five years and how you want those to evolve?
Yeah. I think that’s a fair question, Mike. Just to give a little background, what I’d said is that our long term strategy as we build the business out both organically and inorganically is to do – progress along two definitive directions. The first is to build out comprehensively the three big clinical areas that we’ve identified as our focus areas; Cardiovascular, Diabetes, and Restorative therapies. The second was to expand along the continuous care in each of these areas. And so, you’ll see us moving in those concurrent directions as we go forward. Now, in response to the specific question, in diabetes for example, today we’re a niche player so to speak in Type 1 Diabetes and patients who require insulin. We see that we’ve got a platform which enables us to step into a broader range of diabetes patients who largely are of type 2. First, through our call center presence which is very significant, which we can broaden to apply to a broader patient group. And the acquisition of Cardiocom actually helps in that endeavor. Second, through our continuous glucose monitoring technology, which we feel, as we improve its technology, we can expand into more and more patient types. And then thirdly, we continue to look at value products in our expansion into emerging markets, which will enable us to come out with lower and lower cost pumps over time, which should again address a broader set of population. I think in these areas we expect to grow organically as well as inorganically and expand our footprint into a broader range of diabetic patients.
In terms of restorative therapies, clearly our strength is our approach into that segment through neuroscience and neurology, which has been our core expertise driven by DBS and other neuromodulation products. From there, we take advantage of the fact that in the U.S. at least, most of the neurosurgeons are spinal surgeons as well. And from that, we have gone into spinal implants as you know and have a built a big franchise there. We are looking around that space both in orthopedics potentially, but also in other areas of neuroscience, in ENT, which have overlapped with that broad category. Again, both organically and inorganically we are looking at these areas to try to fill these gaps and we see considerable opportunity in both of those areas.
And at the same time we are also looking for patient continuum of care movements in all three of these areas where we can look at patient management, post treatment, and also diagnostics specifically related to the therapy that we are talking about.
Mike Weinstein – JPMorgan
One follow-up, if you don't mind, on CoreValve as well. The filing of the extreme risk module, do you know if the FDA has accepted that at this point as an independent filing?
Mike, you will take that?
Well, they certainly accepted the submission. How they are going to treat the approvals they have not decided yet. But as we have said all along, as the data becomes available we would submit it in its modules and we have now completed the extreme risk submissions.
Your next question comes from the line of Bob Hopkins with Bank of America.
Bob Hopkins - Bank of America
So two quick questions, one on ICDs and one on emerging markets. First just on ICDs, am I in the ballpark in estimating that the issue around bulk purchasing this quarter may be impacted you by $15 million to $20 million, is that roughly right?
Bob, this is Gary. It's hard to be real specific but the reality is, when you look at below the normal levels, that’s probably even a little bit light, it's probably a little bit more than that in fact, than those impacted. So it's obviously hard to say because there is a range that we have but if we look at kind of a normal level, that’s even probably light.
Bob Hopkins - Bank of America
Okay, thank you. And then on emerging markets, I just want to make sure I understand exactly what you are saying because obviously emerging markets are now driving well over half the total company's growth. So could you just go into a little bit more detail on, for example, what happened in India this quarter? And then also what exactly are you expecting for emerging markets growth in 2014? And to the previous question, is 2014 a year given what is going on in China, will you think there is a little bit of extra risk to that growth rate this year and then more confidence long-term? I just would love you to put emerging markets in better perspective.
Well, look our outlook for emerging markets overall has not changed. We are confident that we can deliver between 15% and 20% quite reliably, and are striving to make that thing 20% or more. And in certain regions we actually have shown consistency at over 20% for an extended period of time. China, we haven’t been able to do that although our growth rate has consistently been 15% or better and have touched 20% every so often. And China is the biggest market, so we are very focused on driving that up as quickly as possible. Our plans are actually looking at increasing China's performance on a stead basis through the coming quarters and into next year. So if anything, we are expecting that we are closer to 20% rather than the other way around.
You know there may well be issues to do with government policy and all of that but in general healthcare is a tremendous need in China and access to healthcare is a big focus of the government. And we are making investments within China. As you know in our Kanghui acquisition, we’ve done the Life Tech partnership as well, as well as put in direct sales people in certain regions to access low tier or second tier cities. So we’re going full board in China and we expect the growth rate in fact to gradually and steadily improve over the next several quarters. So we’re pretty confident about our China outlook as well as overall emerging markets outlook.
Now to do with India and a little bit to do with Latin America, I think there were two distinct issues there. Latin America was clearly one in which we’re transitioning from indirect to direct sales in certain countries and that happened in the middle of the quarter and as that resolves itself, which it will, I bet this quarter or next, we should be on track and not really be seriously impacted. In India, the bigger issue other than the distributor transition which we also went through for other reasons, is that the government has imposed a very low ceiling on pricing for some of the stents. Now we’re working with the government and we’re working with our customers there to come up with a clear strategy through which we can address that market, but in the first and then the last couple of quarters I’d say, it was a dramatic change to the system and essentially it forced sales from not only us but all multinationals.
We think we’re turning that around and going forward we expect that situation to ease a little bit. On India as well, it’s important to point out that although Coronary being the biggest business suffered a pretty big headwind because of this, the rest of the businesses, all of them, from CRDM to Spinal to Surgical Technologies, all of them actually have been growing strong double digit and area continuing to take a bigger and bigger share of our India business. And over time, that will start to mitigate any volatility that we’d see in the stent market. So again our overall emerging market strategy is not changing. We’re expecting to grow fairly steadily in the high teens, mid to high teens and eventually to 20% and beyond. And we expect to report regular progress as we go forward.
Your next question comes from the line of Kristen Stewart with Deutsche Bank.
Kristen Stewart – Deutsche Bank
Just wanted to focus in on the Diabetes business. I guess first I was just curious as to why you’re now breaking out from Restorative Therapies, if it’s foreshadowing any potential consideration that you guys might be looking to potentially I guess spin it off or something else? And then secondly, I guess just with the 530G, you had mentioned in the prepared remarks, Omar, that you’re expecting approval in the fiscal year and I had thought previously expectations were for the end of the calendar year. So I just wanted to double check on that and just get your updated thoughts on timing there.
First, the separation of the Diabetes, that is driven purely and completely by the consideration of how our customers are situated. And like I said, we’re focused on three customers which Cardiovascular, Restorative Therapies broadly encompasses neurology and orthopedics and associated technologies and Diabetes which is a different customer. That’s the reason why we broke it out into three so that it will give us more focus and clear view distinct areas so that we can drive both inorganic and organic growth in each of the areas in the way that I described. So anything in diabetes is going to fill out the platform and approach more and more patients because we consider that to be a key area of growth for us. So I want to make that very clear, that the purpose of this was just looking at our customer base in a logical and rational way and grouping them around certain types of customers who will look at common components of our technology. And therefore through that we can take advantage of our size and scale in addition to being really focused around those customers.
In terms of the approval, we’ve been saying the fiscal year, I think since last quarter, I think prior to that, we were expecting it earlier. We might have said so, but ever since last – at the end of Q4 we’ve been saying this fiscal year. That has not changed. We think that we in fact can get this on the market before the end of the year. Again, this is not completely in our hands so I cannot say definitively because there is lot of variables here. But we are working closely with the FDA and we are making progress and we are pretty confident that we can get this released within the fiscal year. When we do, we expect immediate traction both from an acceptance of the new product which has had considerable outside the U.S. where it's available, and also from the recognition of all the deferred revenue that we have had for the past -- over two quarters now. So that’s the overall outlook, Kristen.
Kristen Stewart – Deutsche Bank
Okay, and then at what point, I guess with the 530G, if that does kind of slip further, where might you make a decision just to perhaps move forward with, I think it's the 640G?
No, I think we are not considering that yet. You know we feel that at this stage the 530G is well on its way to approval and we think it's an unlikely scenario that we would have to skip it completely. I think the patient benefits of that have been proven to be quite dramatic, both in commercial use in Europe and as well as some recent papers that have been published in the New England Journal, I think it was last quarter. And so we are pretty committed and the FDA is working together with us to get this to market. So I think skipping it is a very unlikely scenario at this point.
Yeah, Kristen, just to add to Omar's comment, the FDA's issues are not around the 530G itself, I think they are also very supportive that it's a good product, obviously it's more around our quality systems which is what we are having to do the work on. So I agree with Omar, I mean we have no plans on not launching the 530G. The only question is when and that’s what we are working with the FDA.
Your next question comes from the line of David Roman with Goldman Sachs.
David Roman - Goldman Sachs
Omar, in your prepared remarks you talked a little bit about stabilization in Europe but you also highlighted some of the Medtronic specific efforts to leverage your scale across different regions and different product lines. Could you maybe just go into a little bit more detail there on what you are referencing? I think when we met, I remember we sat with Rob at PCR in May, he talked about a few examples of customer contracting. But maybe you could provide just a little bit more detail on how that might impact your business quantifiably over time?
Yes, just to give you a perspective on what that is. That is essentially working with major customers, primarily hospital systems in Europe, and contractually managing cath labs for them. And I think that gives us the ability to work with the customer very directly to improve their overall efficiency. We have been making some announcements along these lines fairly soon here. So we will wait to give you more details on that event when we are ready. But again in a nutshell, what this does is that it allows us to work with customers on a much broader basis than before and in fact be their partners in improving the overall efficiency of delivery. And so some degree it certainly helps us get some independent revenue streams as well as build closer relationship with clinical customers or the physicians in those accounts as well.
As I have said in the prepared remarks, this includes everything from the efficiency of their cath lab to how [products] are sourced to managing the way in which products are ordered and stocked. And we are building up our technology base to be able to support the various capabilities. There will be some added benefit of our products but the primary perspective here is to provide an overall solution to those customers.
David Roman - Goldman Sachs
And then I guess a follow-up just along similar lines. You also talked about on some of the new product launches, particularly in CRM, that you were awaiting new contracts and looking to obtain price premiums on a number of those products you were launching. Could you maybe just talk a little bit about the dynamic in getting price premiums right now? What is the environment like for that? What type of price premiums do you think you can obtain versus historical averages and how are you balancing that with sort of the cross-selling model?
Well, that’s two different things. First of all, on pricing, the initiatives that we started on a couple of years ago was to be very granular about the economic value, clinical and economic value for our products. And these products, although the development started long before we started to look at it that way, clearly have got both clinical and economic value for which we have evidence. And so we expect to get pricing that is objectively determined in relation to the economic and clinical benefits that these products have. And I think that is an important consideration that we do not want to walk away from just because the quarter end or stuff like that.
I think we work too hard, both in product development and in the generation of evidence to not make sure that that counts. And so that is still part of the issue here that we’re in the process of making that case and we feel confident that we’ll be successful in that we’ll drive up pricing. That’s separate from our overall consolidated approach to customers which is continuing the success. Our growth in accounts with full CBG contracts continues. And this enhancement in the product can only help in that endeavor. I think both Gary and Mike can perhaps -- this is an important question, I’d like both of them to maybe chime in a little bit with any thoughts. Maybe Mike you want to go first?
So just on the question of price increases, some of the features that we’ve added for example is adapted CRT into the Viva product line for all of our high power CRT devices. That actually can eliminate less ventricular pacing in the patient and has been clinically demonstrated to improve CRT response and reduce heart failure hospitalization. And I think you’re probably aware that that 30-day hospital admission window is a very key area focus for hospitals in the U.S and even longer term the ability to keep patients from coming back into the hospital for heart failure re hospitalizations is a big issue. The fact that we can able to demonstrate this, meaning that we would like to accrue the benefits of that enterprise increase.
Now, most hospital systems have put in place technology review committees to rigorously look at these questions because they’re obviously not interested in paying price premium unless it’s for proven benefits. And so that takes some time and that’s exactly what we’ve seen happen. So for hospitals that have chosen in the past to do bulk purchases of product, they basically are waiting to go through their cycle, don’t want to bulk old product because they know they would rather replace it with a new product, but have to get through their pricing committees in order to get approval. So that’s been one of the main issues in the quarter and the same thing applies to our Evera product line with its shock reduction production technology. So that really is the dynamic that was playing out in the quarter.
I really don’t have much to add to what Mike just indicated. As he indicated, the biggest issue was getting people on contracts. And that’s the change that’s probably occurred over in the industry over the last several years where what used to be maybe just a little price increase (inaudible) and immediately the doctors to make that call and that decision. Obviously with the buying decisions now in hospitals, these committees are more engaged in that process and ensuring that the products have the technology. So as he indicated, that slows down the process slightly. It doesn’t mean you don’t get the price increases. It just means that you have to go through certain processes.
We’ve gone past the top of the hour. Let’s take two quick questions before wrapping up.
Your next question comes from the line of Larry Biegelsen with Wells Fargo.
Larry Biegelsen - Wells Fargo
So it looks like, excluding the CoreValve stocking, you grew slightly below 3% this quarter. And so I guess, Omar, my question is what gives you the confidence that you’ll be able to grow 3% to 4% in fiscal year 2014, especially if you assume that there is an injunction in Germany with the CoreValve litigation and you’ll lose approximately maybe $40 million to $50 million in sales? So it would be helpful to hear from you how you see the rest of the year playing out and what gets you to the 3% to 4%? Thanks.
We tried to lay out the three areas where we had pressures in a very distinct fashion. Certainly Diabetes is pretty straightforward. There’s a pretty big chunk, all of which is probably more than offsetting CoreValve issue that we may be facing in the next three quarters just and we expect even more out of that. So agreed, we need the approval, and if we don’t get approval there’ll be pressure there. But we’re pretty confident that we will. And that’s a very distinct thing that we will all look at very clearly. I think in terms of neuro, we’re already seeing traction. Again as we said, level by itself, at the same level or close to any pressures that we may face in Germany. So that alone again can -- is likely to give us some tailwind if you like in the remaining three quarters, and we are already seeing that. So this is not something that we are waiting for because we have already shifted to the new product in manufacturing and we are launching it as we speak. And although, again, as we said, that it's very early in the quarter but all the evidence points to the fact that we will get what we are expecting out of that.
And then finally, we come to CRDM and we explained what happened here. You know the bulk purchases were at their lowest levels and the inventory levels are down. Again, nothing for certain here, but if you just look at this thing in a fairly objective basis over time, we expect those levels to recover and we expect the pricing premiums because we have already experienced that in places where customers have been through the technology review committees and so on. And as we go through next quarter we expect that to come through. So we have go three areas which are very clear in their pickup in the remaining half of the year. Granted there will be some pressure out of CoreValve but we feel that these three alone are sufficient to more than offset that pressure. And in addition to that I highlighted series of other initiatives that will come to fruition with a year for which we expect revenue. So again, we laid all of that out and we in our analysis feel that the guidance that we provided is quite achievable.
Larry Biegelsen - Wells Fargo
Great. That’s very helpful. And just lastly for me, Chris, if Chris O'Connell is in the call, I just wanted to ask about the competitive bidding for insulin pumps and just wanted to confirm that you feel that your pumps are pretty well protected by any competitive bidding that could be implemented in January 2014? Thanks.
First of all, let me take that. That is correct. We feel pretty protected that that’s not part of the competitive bidding process. It's a much more unique product, it's not commoditized even close in that sense. And we have got support from the physician community and the healthcare agencies in that respect. So we don’t really any serious risk of the pump falling under competitive bidding. Chris, anything you want to add....?
No, I think that’s right. It's really about the -- to find the categories of pumps that are going to be subject to competitive bidding. That’s an ongoing discussion with CMS.
Your final question comes from the line of Matt Taylor with Barclays Capital.
Matt Taylor - Barclays Capital
I was just interested to see if you could talk a little bit more about your transition to positioning yourself as really a provider of solutions? And maybe you could help us understand, I know you said you had some announcements coming up, but can you talk about over time what portion of revenue you think you are going to be able to derive from those kinds of services? Is it going to be really small and adjunct or could it to be an actual meaningful revenue piece over time?
Well, over time we think it will be meaningful but it is going to take some time. And let me highlight the Cardiocom acquisition. That’s a pretty good example of the sorts of things which you are going to expect from us. Here is a company which is a leader in terms of disease management. It has complementary services to what we already have. It addresses a broader range of patients than the ones we do. And you put the two together, both synergy as well as incremental revenue from an independent source. So that’s the kind of activity that we would like to do, which leverages what we have but is not solely dependent on what we have but in fact grows it independently.
And in the beginning we expect just one plus one if you like. In the long-term we expect one plus one and more through the synergies that we expect to derive. And we expect to move in that direction in those two areas in disease management which essentially means looking across the continuum of care and primarily at this stage looking at patient management beyond the therapy of people who have the same kind of disease but without our devices. And have a structure through which we can manage those patients. And hospital systems and payers around the world recognize that managing these patients is critical to us being able to manage the overall cost of care, both in the U.S. and around the world.
Hospital efficiency is a different area where we’re looking primarily at making sure that hospitals are working in the most efficient manner as possible. And our initial focus is in the area of cardiology because that’s where we have our biggest strength. And we’ve had some initial success in Europe in not only getting those contracts, but starting to execute them. So we expect that too to become a larger and larger portion of our business.
The independent revenue streams will be small to start with. Over time it will grow. I think the impact that it will have to synergy on the sales of our regular devices perhaps will be more and more meaningful. But we’d like to see what we get out of this as we go forward. But that’s potentially the strategy. We’re not taking in big numbers for this stage. That is an area we’re focused in and long term we think in both of these areas there’s big opportunities for us to tap into in terms of available patients who need the care and both from the government and payers for us to be able to provide such solutions.
Finally, maybe a lot is going to depend on how quickly the U.S in particular moves from a pay per procedure system to a pay per value system. The quicker that shift occurs, the greater will be the meaningfulness (inaudible) of this revenue. If that happens quickly, you’ll see much quicker growth in that area from us. If that happens slowly, it will take a little more time. so there are too many factors for me to say definitively, but those are some of the considerations.
All right, let me conclude right now. Thanks again to all of you for your questions and on behalf of our entire management team, I’d like to thank you for your continued support and interest in Medtronic. We look forward to updating you on our progress on our Q2 call which we anticipate holding on November 19. Thank you all very much.
This does conclude today’s conference call. You may now disconnect.
Copyright policy: All transcripts on this site are the copyright of Seeking Alpha. However, we view them as an important resource for bloggers and journalists, and are excited to contribute to the democratization of financial information on the Internet. (Until now investors have had to pay thousands of dollars in subscription fees for transcripts.) So our reproduction policy is as follows: You may quote up to 400 words of any transcript on the condition that you attribute the transcript to Seeking Alpha and either link to the original transcript or to www.SeekingAlpha.com. All other use is prohibited.
THE INFORMATION CONTAINED HERE IS A TEXTUAL REPRESENTATION OF THE APPLICABLE COMPANY'S CONFERENCE CALL, CONFERENCE PRESENTATION OR OTHER AUDIO PRESENTATION, AND WHILE EFFORTS ARE MADE TO PROVIDE AN ACCURATE TRANSCRIPTION, THERE MAY BE MATERIAL ERRORS, OMISSIONS, OR INACCURACIES IN THE REPORTING OF THE SUBSTANCE OF THE AUDIO PRESENTATIONS. IN NO WAY DOES SEEKING ALPHA ASSUME ANY RESPONSIBILITY FOR ANY INVESTMENT OR OTHER DECISIONS MADE BASED UPON THE INFORMATION PROVIDED ON THIS WEB SITE OR IN ANY TRANSCRIPT. USERS ARE ADVISED TO REVIEW THE APPLICABLE COMPANY'S AUDIO PRESENTATION ITSELF AND THE APPLICABLE COMPANY'S SEC FILINGS BEFORE MAKING ANY INVESTMENT OR OTHER DECISIONS.
If you have any additional questions about our online transcripts, please contact us at: email@example.com. Thank you!